Array-CGH and breast cancer.
The introduction of comparative genomic hybridization (CGH) in 1992 opened new avenues in genomic investigation; in particular, it advanced analysis of solid tumours, including breast cancer, because it obviated the need to culture cells before their chromosomes could be analyzed. The current generation of CGH analysis uses ordered arrays of genomic DNA sequences and is therefore referred to as array-CGH or matrix-CGH. It was introduced in 1998, and further increased the potential of CGH to provide insight into the fundamental processes of chromosomal instability and cancer. This review provides a critical evaluation of the data published on array-CGH and breast cancer, and discusses some of its expected future value and developments.
van Beers
Erik H
EH
Division of Experimental Therapy, Netherlands Cancer Institute NKI-AVL, Amsterdam.
Nederlof
Petra M
PM
D001943:Breast Neoplasms / Q000235:genetics*; D004273:DNA, Neoplasm / Q000235:genetics*; D005260:Female; D018628:Gene Dosage; D020869:Gene Expression Profiling; D020022:Genetic Predisposition to Disease; D006801:Humans; D046228:Microarray Analysis; D009693:Nucleic Acid Hybridization; D014407:Tumor Cells, Cultured
D004273:DNA, Neoplasm